Cytometry by Time-of-Flight for Profiling Therapeutic Response in Colorectal Cancer: Strengths, Limitations, and Translational Challenges

Technological Principles and Comparative Positioning of Mass Cytometry

Principles and workflow of mass cytometry. Mass cytometry, or CyTOF, is a high-parameter technology that analyzes individual cells by using mass spectrometry instead of fluorescence, allowing for the simultaneous measurement of over 40 proteins in a single cell (9). The process begins with the critical step of panel design, where antibodies targeting specific proteins are conjugated to purified heavy metal isotopes, primarily from the lanthanide series. The selection of which metal to pair with each antibody is strategic; low-abundance proteins are tagged with isotopes in the instrument’s highest sensitivity range to ensure detection, while highly expressed markers are assigned to less sensitive masses (7). Following panel design, samples like tumor biopsies are dissociated into single-cell suspensions, stained with the antibody cocktail, and treated with reagents like platinum-based intercalators to identify dead cells and iridium to label DNA for event identification. A key technique, sample barcoding, uses unique palladium isotope combinations to label different samples, allowing them to be pooled and stained together to ensure uniformity and increase throughput (10).

The next stage is data acquisition using the CyTOF panel. The prepared single-cell suspension is nebulized into a fine aerosol directing to an argon plasma torch operating at over 6,000 K. This extreme temperature atomizes each cell, creating a cloud of its constituent ions, including the heavy metal reporters from the antibodies. This ion cloud is then passed through a quadrupole that filters out common, low-mass biological ions, isolating the heavy metal reporters of interest. These purified ions enter the time-of-flight (TOF) mass spectrometer, where they are accelerated by an electric field. Because lighter ions travel faster than heavier ones, the instrument can precisely identify each isotope by measuring its flight time to the detector. The detector then counts the ions of each mass that originated from a single cell, generating a quantitative, multi-parameter protein profile for that specific cell (11). A schematic representation of the CyTOF workflow is shown in Figure 1, reproduced with permission from Bendall et al. (9).

• Download figure
• Open in new tab
• Download powerpoint

Figure 1.

Overview of the Cytometry by Time-of-Flight (CyTOF) workflow. Individual cells are stained with antibodies conjugated to distinct heavy metal isotopes, nebulized into an argon plasma, atomized and ionized, and analyzed by time-of-flight mass spectrometry. The resulting ion signals are converted into quantitative, high-dimensional single-cell proteomic data. Reproduced from Bendall et al. “Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum,” Science 332: 687-696, 2011 (DOI: 10.1126/science.1198704), with permission from the author.

The fundamental advantage of CyTOF over traditional flow cytometry is the elimination of spectral overlap. Fluorescent dyes have broad emission spectra that spill into adjacent channels, requiring complex mathematical compensation and limiting the number of markers that can be measured simultaneously. On the other hand, the TOF mass spectrometer can easily distinguish between metal isotopes with a difference of just one atomic mass unit, producing clean, discrete signals with negligible overlap (11). This circumvents the need for compensation, simplifies experimental design, and dramatically expands the multiplexing capacity (7). Ultimately, this enables the deep, high-dimensional cellular profiling required to unravel the complexity of biological systems like the tumor microenvironment.

Comparative technological analysis. To fully appreciate the role of mass cytometry in clinical oncology research, it is essential to position it within the broader landscape of single-cell analysis technologies. The three dominant platforms – conventional flow cytometry, mass cytometry (CyTOF), and single-cell RNA sequencing (scRNA-seq) – each offer a unique set of capabilities, with distinct advantages and limitations. The choice of technology is not a matter of inherent superiority, but rather a strategic decision dictated by the specific biological question being addressed.

CyTOF versus flow cytometry. Mass cytometry is a direct evolution of flow cytometry, designed specifically to overcome its primary limitation: spectral overlap (12). The most significant advantage of CyTOF is its vastly superior dimensionality. While expert-level conventional and spectral flow cytometry can now approach 20-50 parameters, CyTOF routinely enables the analysis of 40-50 markers in a single panel, with a theoretical capacity for over 100 (7). This is possible because the discrete signals from atomic mass isotopes eliminate the significant spectral spillover and cellular autofluorescence that plague fluorescent systems, thereby simplifying panel design and removing the need for complex compensation calculations (7). However, this high-dimensional capability comes at the cost of speed and cell viability. Conventional flow cytometers are high-throughput instruments, capable of analyzing tens of thousands of cells per second, whereas CyTOF is significantly slower, typically analyzing several hundred to a thousand cells per second (13).

CyTOF versus scRNA-seq. This comparison highlights a fundamental trade-off between measuring the functional effectors of a cell (proteins) versus its transcriptional intent (mRNA). CyTOF provides a direct, quantitative measurement of protein abundance, including crucial post-translational modifications like phosphorylation, which are the ultimate mediators of cellular function and signaling (14). scRNA-seq, on the other hand, measures mRNA transcript levels, which do not always correlate with protein expression due to complex post-transcriptional and post-translational regulation (15). Another key difference is the scale of analysis. CyTOF can analyze millions of cells per sample, providing the statistical power necessary to robustly identify and quantify very rare cell populations, which is often critical in immunology and oncology. In contrast, scRNA-seq typically analyzes a much smaller number of cells (thousands to tens of thousands) and suffers from a “drop-out” phenomenon where lowly expressed transcripts may not be detected, making it less reliable for rare cell analysis (16). The strength of scRNA-seq, however, lies in its unbiased, discovery-oriented nature. While a CyTOF experiment is limited to a pre-selected panel of ~50 proteins, scRNA-seq provides a global snapshot of thousands of expressed genes, allowing for the discovery of entirely novel pathways and cellular markers without prior hypotheses (16).

The distinct strengths of these platforms have led to the realization that the most powerful approach often involves their synergistic use. Emerging multi-omic technologies, such as cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq), attempt to bridge the gap by simultaneously measuring a panel of surface proteins (via antibody-oligonucleotide conjugates) and the transcriptome in the same cell (17). However, CITE-seq is still limited by the lower cell throughput of sequencing and typically focuses on surface proteins, whereas CyTOF can readily measure intracellular and nuclear targets (16).

This comparative analysis reveals a crucial distinction between technologies designed for broad discovery and those designed for deep profiling. scRNA-seq excels as a discovery tool, casting a wide, unbiased net to identify which of thousands of genes might be relevant to a biological process. CyTOF, in contrast, is the premier tool for deep profiling. It uses a hypothesis-driven, pre-selected panel of markers to precisely and robustly quantify the frequency, phenotype, and functional state of known cellular hierarchies across millions of cells. A comparative analysis of the key single-cell technologies used in clinical oncology research is presented in Table I.

Strengths and weaknesses of CyTOF in a translational context. Mass cytometry (CyTOF) offers several compelling strengths that support its potential for clinical translation, particularly in oncology. One of its primary advantages is the ability to extract rich, high-dimensional data from limited clinical samples – an especially important feature when working with small tumor biopsies. Unlike conventional flow cytometry, which requires multiple tubes to analyze dozens of markers, CyTOF can measure over 40 proteins in a single assay, making it uniquely suited for deep immunophenotyping of the tumor microenvironment (18). Another key strength is its capacity to assess post-translational modifications (PTMs), such as phosphorylation, through the use of phospho-specific antibodies. This enables a functional readout of cell signaling activity – something that genomic or transcriptomic assays cannot provide (19). Additionally, the use of stable metal-isotope tags allows for long-term sample preservation and transport, facilitating centralized analysis in multi-center clinical trials while minimizing variability and logistical complexity (20).

Despite its exceptional analytical power, CyTOF faces several important limitations that currently constrain its routine clinical implementation. These challenges reflect technical, logistical, economic, and interpretative barriers that must be resolved before it can be translated into routine colorectal cancer care.

Throughput and scalability represent fundamental constraints. Compared with conventional flow cytometry, CyTOF acquisition speed is substantially lower, typically analyzing several hundred cells per second (21). While sufficient for deep immune profiling, this limits feasibility for high-throughput diagnostic workflows. Another intrinsic limitation is the destructive nature of mass cytometry. During CyTOF acquisition, cells are atomized and cannot be recovered for downstream applications such as functional assays, live-cell sorting, or longitudinal culture (7). This precludes experimentation on the same sample and necessitates parallel sample allocation when complementary analyses are required, which can be challenging when tissue availability is limited.

CyTOF is also highly sensitive to pre-analytical and analytical variability. Differences in tissue dissociation, fixation, cryopreservation, antibody conjugation, staining protocols, and instrument calibration can introduce batch effects that confound biological interpretation (13, 21). Without standardization, such variability may undermine reproducibility across laboratories and limit comparability between studies or clinical trials, thereby restricting the generalizability of findings.

Perhaps the most significant translational barrier is the complexity of data analysis and interpretation. Mass cytometry generates high-dimensional single-cell datasets that cannot be reliably analyzed using traditional manual gating approaches. Instead, advanced computational methods – including dimensionality reduction, unsupervised clustering, and machine-learning–based classification – are required. These analyses demand specialized bioinformatics expertise and infrastructure, which are not routinely available in clinical laboratories. Moreover, variability in analytical pipelines and parameter choices can lead to inconsistent results, complicating validation and clinical reporting. Beyond analytical complexity, a critical translational gap persists between biological insight and clinical actionability. Many CyTOF-derived biomarkers in CRC – including immune cell subsets, signaling states, and spatial interaction metrics – remain largely hypothesis-generating rather than clinically validated, and converting these multidimensional signatures into simplified, decision-ready outputs suitable for routine oncology practice remains an unresolved challenge (7, 12, 22, 23).

Lastly, a major limitation is the cost and infrastructure burden. CyTOF platforms require substantial capital investment, specialized laboratory infrastructure, and continuous access to metal-conjugated antibodies and consumables, resulting in high per-sample costs. In addition, operation and maintenance demand highly trained personnel, limiting availability to specialized centers and complicating deployment in resource-constrained or decentralized clinical settings (7). These financial barriers necessitate clear demonstrations of clinical utility and cost-effectiveness before widespread adoption can be justified.

Cellular and Microenvironmental Determinants of Chemotherapy Response in CRC

Therapeutic landscape of CRC: Standard regimens and targeted agents. The therapeutic backbone for metastatic CRC (mCRC) consists of cytotoxic chemotherapy, often combined with targeted biological agents depending on the molecular profile of the tumor (24).

Fluoropyrimidine-based regimens. Combination chemotherapy regimens are the cornerstone of first-line treatment. The most common are FOLFOX, which combines 5-FU, leucovorin, and oxaliplatin, and FOLFIRI, which substitutes irinotecan for oxaliplatin. These regimens may also be given in combination with a monoclonal antibody. 5-FU is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis and repair. Oxaliplatin is a platinum-based agent that forms DNA adducts, leading to apoptosis, while irinotecan is a topoisomerase I inhibitor that causes DNA strand breaks.

Anti-epidermal growth factor receptor (EGFR) therapy. The EGFR is a receptor tyrosine kinase that is overexpressed in approximately 70% to 80% of colorectal cancers and is involved in driving proliferation, survival, and metastasis (25). Monoclonal antibodies such as cetuximab (a chimeric IgG1) and panitumumab (a fully human IgG2) bind to the extracellular domain of EGFR, preventing ligand binding and subsequent downstream signaling. However, their efficacy is restricted to patients with RAS wild-type tumors, as mutations in downstream effectors like KRAS and NRAS lead to constitutive pathway activation, rendering upstream EGFR blockade ineffective (26).

Tumor-intrinsic factors modulating chemotherapy response. Tumor cells can evade therapy through a variety of pre-existing (intrinsic) or acquired molecular alterations. These mechanisms include genetic mutations, altered drug transport and metabolism, and evasion of cell death pathways (27).

Signaling pathway dysregulation. The EGFR signaling network is a prime example of how genetic alterations confer resistance. Activation of EGFR triggers multiple downstream cascades, including the RAS-RAF-MAPK and PI3K-PTEN-AKT pathways, which are critical for cell growth and survival. Mutations in key nodes of these pathways, such as KRAS (found in ~40% of CRCs), NRAS (~3-5%), BRAF (specifically the V600E mutation), or PIK3CA, lead to constitutive signaling that is independent of EGFR activation. Consequently, tumors harboring these mutations are resistant to anti-EGFR therapies like cetuximab (26).

Drug transport and metabolism. One of the most well-characterized mechanisms of multidrug resistance (MDR) is the overexpression of drug efflux pumps belonging to the ATP-binding cassette (ABC) transporter superfamily. P-glycoprotein (P-gp), also known as multidrug resistance protein 1 (MDR1) or ABCB1, is a prominent member of this family. P-gp is an ATP-dependent p efflux pump with broad substrate specificity that actively transports a wide range of xenobiotics, including chemotherapeutic agents like oxaliplatin, irinotecan, and 5-FU, out of the cell (27). Overexpression of P-gp reduces intracellular drug concentration below therapeutic levels, enabling cancer cells to evade cytotoxic effects of chemotherapy and survive (28).

Evasion of apoptosis and altered protein stability. Chemotherapy primarily functions by inducing catastrophic cellular damage that triggers programmed cell death, or apoptosis. Cancer cells can develop resistance by dysregulating this process, for example, by upregulating anti-apoptotic proteins like Bcl-2 or downregulating pro-apoptotic proteins, thereby raising the threshold for cell death (29). More recently, novel proteomic mechanisms of resistance have been identified. Studies using protein folding stability profiling have shown that the thermodynamic stability of specific proteins can be linked to drug sensitivity. In CRC models, 36 proteins were found to be differentially stabilized between oxaliplatin-sensitive and -resistant samples, and 10 of these had been previously linked to chemoresistance. The overlap between these proteins and those identified by conventional expression-level analysis was only 30-40%, indicating the two approaches provide complementary information (30).

TME as a modulator of therapeutic efficacy. The TME is not a passive bystander but an active participant in tumorigenesis as well as in therapeutic response. It comprises a complex ecosystem of non-malignant cells and non-cellular components that can profoundly influence cancer cell behavior and shield them from chemotherapy (2).

Cellular components. The TME is populated by a diverse array of cells. CAFs are a major stromal component that can promote tumor growth and invasion through the secretion of growth factors and remodeling of the extracellular matrix (31). The immune infiltrate is highly heterogeneous and can have dual roles. While cytotoxic T lymphocytes (CTLs) are critical for anti-tumor immunity, the TME is often dominated by immunosuppressive populations, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) (32). TAMs, in particular, can adopt an M2-like, pro-tumorigenic phenotype, promoting angiogenesis, suppressing T-cell function, and contributing directly to chemoresistance (33).

TME-mediated chemoresistance: The TME confers resistance through multiple mechanisms.

Soluble factor secretion: TAMs and other immune cells can secrete cytokines like Interleukin-6 (IL-6), which activates the STAT3 signaling pathway in colorectal cancer cells, leading to the upregulation of anti-apoptotic proteins and chemoresistance (33).

Extracellular matrix (ECM) remodeling: CAFs can produce a dense, fibrotic ECM, a process known as desmoplasia. This dense matrix can act as a physical barrier, impeding the diffusion of chemotherapeutic drugs to the tumor cells. The altered ECM can also create hypoxic regions, which further promote resistance and an immunosuppressive environment (34).

Direct cell-cell contact and crosstalk: Interactions between tumor cells and stromal cells can activate pro-survival signaling pathways. For example, crosstalk between CAFs and tumor cells can regulate the TME to suppress tumor progression through cytokines like CXCL12 and SLIT2 (30). The intricate network of interactions within the TME creates a protective niche that allows cancer cells to survive therapeutic effect (35).

Early Immune Remodeling and Spatial Niches in Colorectal Cancer Defined by Mass Cytometry

In a spatial mass cytometry study of eight pT1 colorectal cancers across matched histologic continua (from normal mucosa to low-grade dysplasia, high-grade dysplasia, and carcinoma), Roelands et al. showed progressive accrual of stromal and innate compartments with neoplastic advancement. More specifically, dendritic cells, monocytes, granulocytes, innate lymphoid cells, fibroblasts, and vascular elements all increased in density, whereas total macrophage burden remained comparatively stable. Within CD68⁺ cells, mass cytometry resolved four macrophage phenotypes (HLA-DR, CD204/MSR1, CD163), revealing a compositional shift characterized by a decline in HLA-DR⁺ macrophages (from approximately 25-30% in normal/transition areas to 5-10% in carcinoma), an expansion of HLA-DR⁻ CD204⁺ populations (from roughly 10-15% to 25-30% for HLA-DR⁻CD163⁺CD204⁺ and from 5-10% to 15-20% for HLA-DR⁻CD163⁻CD204⁺), and a biphasic HLA-DR⁻ CD163⁺CD204⁻ subset peaking near low-grade dysplasia (15-20%) before declining toward carcinoma (5-10%). These values represent semi-quantitative estimates derived from regional frequency plots. Collectively, the findings support that macrophage composition, rather than total macrophage density, better tracks epithelial transformation at the earliest stages (36).

Across two independent mass cytometry–based spatial datasets, Bortolomeazzi et al. (multiregion MSI-H/dMMR CRC) and Zhang et al. (metastatic CRC), clinical benefit from PD-1 blockade correlated more with organized myeloid–lymphoid niches than with bulk T-cell quantity. Durable-benefit tumors harbored higher abundances of CD68⁺CD74⁺ macrophages, with ~52% of CD74⁺ macrophages forming high-density aggregates (≥5 cells/10,000 μm²) versus ~32% in no-benefit tumors, and PD-1⁺ cytotoxic/proliferating CD8⁺ T cells (GZB⁺ and/or Ki67⁺) localized in closer proximity to PD-L1⁺ CD68⁺CD74⁺ macrophages than to other cells. In metastatic disease, responders were further enriched for C1QC⁺ resident-tissue macrophages (RTMs) along a graded pattern (MSI_R > MSS_R > MSI_NR > MSS_NR) and formed proximal RTM–CD4⁺ neighborhoods in which CD4⁺ cells exhibited higher activation markers (CD38, CD57, GZMB, TNFα, PD-1). Together, spatial macrophage phenotypes and short-range adjacency to effector T cells segregated benefit more reliably than bulk CD3⁺/CD8⁺ measurements (37, 38).

Using mass cytometry–derived distance mapping in nine primary CRC tumors, Küçükköse et al. demonstrated that metastatic primaries exhibit denser αSMA⁺ stromal matrices and marked displacement of CD8⁺ T cells from tumor epithelium. The median CD8–tumor-cell distance shifted from ~2 μm (intra-epithelial) in non-metastatic MSI-H cases to ~21-22 μm (stromal-restricted) in metastatic tumors (p=2×10⁻¹⁶). Functionally, granzyme-B expression peaked in intra-epithelial CD8⁺ cells of non-metastatic MSI-H tumors, consistent with fibroblast-rich stroma imposing a physical/biochemical exclusion barrier that dilutes cytotoxic potential at the tumor–immune interface (39).

Complementing these findings, a mass cytometry atlas comparing CRC tumors to distant normal tissues presented by Zhang Y. et al. revealed reciprocal remodeling of innate lineages – enrichment of CD66b⁺(CD16⁺) neutrophils alongside depletion of CD56⁺ NK cells – highlighting a shift toward granulocytic predominance and NK paucity within cancerous regions. In a CRC-dominant MSI-H/dMMR neoadjuvant pembrolizumab trial, Ludford et al. reported early pharmacodynamic readouts in which progressors displayed higher densities of CD45⁺HLA-DR⁻CD15⁺ granulocytes and increased frequencies of TOX^high CD8⁺ T cells, with shorter CD8− granulocyte distances than non-progressors. Their findings implicate granulocytic proximity as a correlate, and potential mediator, of cytotoxic T-cell dysfunction and primary resistance to PD-1 blockade (25, 40).

Systemic Immune Profiling in CRC by Blood-based CyTOF

Using serial CyTOF profiling around laparoscopic resection, Zhou et al. mapped brisk, stereotyped perioperative kinetics in 24 patients. Total T cells dropped on post-operative day (POD) 1 and returned to baseline by POD 3. Monocytes rose on POD 1 with broad HLA-DR downregulation across classical CD14⁺CD16⁻ monocytes – which comprised ~93% of all monocytes – and this suppression persisted in 5 of 10 classical-monocyte clusters through POD 7. NK subsets redistributed: mature CD56^dimCD16⁺ clusters decreased after surgery, whereas CD56^brightCD16⁺ clusters rose by POD 3 and remained elevated at POD 7. Serum IL-6 and IL-10 spiked on POD 1 and stayed above baseline to POD 7. Several perturbations, including HLA-DR^low classical monocytes, intermediate NK gains, and CD8⁺PD-1⁺ activation, had not fully recovered by one week, indicating a sustained and predominantly suppressive systemic program that bulk counts alone would miss (41).

In the chemotherapy setting, Shinko et al. demonstrated a sustained depletion of mature cytotoxic NK cells in 10 patients on FOLFOX: CD56^dimCD16⁺ counts fell from 429.3±88.6 cells/μl (day 1) to 286.5±35.0 (day 3; p=0.0078) and 227.9±54.7 (day 15), remaining below baseline across later cycles (e.g., cycle 6: ~196 cells/μl). In contrast, CD56^bright and CD56^dimCD16⁻ NK populations expanded during treatment. Phospho-signaling in patient NK cells was already skewed at baseline compared to healthy controls, showing increased pSTAT5 in all subsets, decreased pSTAT3 in CD56^dim subsets, elevated pERK particularly in CD56^bright cells, and reduced pP38 across all subsets. These patterns have remained largely unchanged by chemotherapy, suggesting a disease-driven IL-2/IL-15–STAT5 biased signaling state with implications for NK maturation and cytotoxicity (42).

Beyond surgical and cytotoxic stressors, Gao et al. profiled 4.75 million peripheral CD45⁺ cells from 73 stage II (29 right-, 44 left-sided) and 21 stage III CRC patients using a 37-marker panel, resolving 31 phenotypes and a prominent set of circulating T:monocyte complexes (CD3⁺ paired with CD14/CD16). Complexes were more frequent in stage II than stage III (p=0.023), whereas total circulating T-cell and monocyte frequencies did not differ, arguing that complex formation is a more sensitive systemic readout. Side- and CMS-specific signatures emerged, such as left-sided stage II tumors with more CD8⁺ central-memory T:non-classical-monocyte complexes and fewer CD8⁺ terminal-effector T:classical-monocyte complexes while CMS1 tumors had increased CD8⁺ terminal-effector T:classical-monocyte complexes. This data supports the utility of CyTOF-resolved composite phenotypes to capture systemic heterogeneity linked to tumor biology (43).

Tumor-intrinsic Signaling States and Organoid Modeling by CyTOF

Across an isogenic human colon organoid series, Sell et al. profiled ~10,000 single cells per genotype under ±Wnt/±EGF for 48 h and aligned readouts along an EphB2-defined differentiation axis. KRAS-mutant lines consistently showed elevated pMEK, pERK, and pS6 without commensurate pAKT/p4E-BP1 changes, and EGF withdrawal paradoxically increased pERK despite lower MAPK-target transcription – reflective of internal feedback signature rather than simple ligand dependence. SMAD4 loss raised pSMAD1/8 while BMP-target transcription fell, again indicating decoupling between phosphorylation and transcriptional output. Variance partitioning was analytical rather than descriptive: differentiation state explained the largest share of signaling variance (approaching ~0.8 for some nodes), whereas medium composition and genotype contributed less at the single-cell level. In 11 patient-derived organoid (PDO) lines (≈5,000 cells/line × 3 media; ~165,000 events), most displayed graded EphB2 distributions; BRAF-mutant PDOs clustered at low-EphB2 (consistent with non-canonical/serrated trajectories), and growth-factor omission shifted susceptible lines toward higher EphB2/LGR5. Two inferences emerged: (i) signaling is state-coupled across genotypes (e.g., MEK/ERK peaks in undifferentiated bins), and (ii) oncogenic drivers constrain the admissible state-space, thereby limiting the apparent impact of extrinsic Wnt/EGF. These findings argue that therapy readouts (e.g., MEK/ERK inhibition) should be stratified by cell state rather than averaged across heterogeneous populations (44).

Complementing this, Brandt et al. used inducible mouse intestinal organoids with KRAS G12V or BRAF V600E and CyTOF-based network perturbations (~160,000 tdTomato⁺ cells over 12 conditions). Unsupervised clustering defined six crypt to villus-like states. pERK was selectively high in clusters 5-6 (Paneth/crypt-like) under KRAS G12V, but uniformly high across all clusters with BRAF V600E, indicating cell-state restriction of KRAS to ERK versus pan-cellular BRAF to ERK drive. Modular response analysis quantified stronger MEK to ERK feed-forward and weaker ERK-mediated feedback in ERK-high clusters (5-6), with the opposite pattern in enterocyte-like clusters (3-4). Functionally, KRAS G12V and GSK3β inhibition each increased the fraction of crypt-like cells (cluster 1), and the combination produced the largest redistribution while reducing the apoptotic cluster 5 – emphasizing that Wnt/β-catenin programs can shift composition toward ERK-permissive states, potentially altering responses to MAPK-targeted agents. At the molecular level, reporter-guided RNA-seq highlighted DUSP1/5/6 as candidate attenuators of ERK in differentiated cells, aligning with the feedback-heavy topology inferred from perturbation data. Analytically, these findings support state-aware targeting, such as feedback-modulating strategies in KRAS tumors vs. broad MEK/ERK blockade in BRAF tumors, and caution against bulk averaging that obscures cell-type–specific wiring (45).

Therapy Response Mapping and Biomarker-guided Combinations by CyTOF/Spatial Mass Cytometry

In a large single-cell co-culture screen, Ramos Zapatero et al. combined thiol-reactive organoid barcoding in situ (TOBis) mass cytometry with Trellis-tree analytics across >10 million PDO cells and >15 million CAFs (from 2,520 cultures run in triplicate), quantifying cell-cycle (pRB/IdU/pHH3), DNA damage (pH2AX/pCHK1), apoptosis (cPARP/cCaspase-3), and PTM-signaling nodes. On-target cytostasis was common – ~83% of PDO/drug conditions showed cell-cycle arrest – yet apoptosis occurred in only ~40% of patient–drug combinations, with responses clustered more by patient than by drug. CAFs frequently blunted apoptosis without preventing DNA damage or arrest, converting chemosensitive PDOs into slow-cycling, drug-tolerant states characterized by decreased MAPK/PI3K (pMEK/pERK/pAKT/pS6/4E-BP1) signaling and increased TGF-β/SMAD, stress-kinase (MKK4 to p38/MK2), and NF-κB signaling, with reduced S-phase entry (IdU, pRB). Analytically, the principal barrier to efficacy was failure to translate genotoxic stress into apoptosis, often stroma-imposed. The authors advocate mechanism-focused, single-cell pharmacodynamics that include stroma, and PTM-signaling signatures, rather than genotype alone, to guide patient-specific combinations that counter CAF-driven protection – for example targeting TGF-β, JNK, or NF-κB axes to re-sensitize to chemotherapy (46).

CyTOF has also mapped checkpoint-responsive T-cell states that suggest rational combinations. In MC-38 tumors, Beyrend et al. showed anti-PD-L1 increased CD8⁺ TILs (from 16.1% to 24.1% of CD45⁺ by day 8) and expanded “TAI” (targetable-activated/inhibited) T-cell subsets co-expressing activating (ICOS, CD69, CD43) and inhibitory (PD-1, LAG-3, NKG2A, CD39) receptors – CD8⁺ TAI ~7% to ~17% of CD8⁺ TILs; CD4⁺ TAI ~8% to ~17% – with granzyme-B-high CD39⁺PD-1⁺ cytotoxic potential. Trajectories placed TAI downstream of CD44^int intermediates, implying further activation rather than new lineage. Co-targeting LAG-3 or agonizing ICOS with PD-L1 blockade improved control/survival and further increased TAI abundance. Importantly, analogous LAG-3⁺ICOS⁺ T-cell phenotypes were detected in human MMR-deficient CRC, supporting clinical PD-(L)1 + ICOS agonist and/or LAG-3 inhibitor combinations and proposing TAI-cell expansion as a mechanistic biomarker (47).

Converging myeloid-axis evidence is provided by Krieg et al., where complement (C3aR) downregulation “heated” the CRC microenvironment, and PD-1 blockade further reprogrammed intratumoral immunity toward type-1 inflammation (elevated IL-12/IFN-γ/TNF-α; reduced IL-22/IL-4) by CyTOF, nominating complement-axis modulation plus PD-1 inhibition as a strategy to convert “cold” MSS CRCs. Spatial pharmacodynamics in mouse models similarly support stromal/myeloid targeting: Kaistha et al. observed that adding anti-CD73 to cytotoxic therapy and PD-L1 inhibition reduced TAM (CD163/CD206), CAF (α-SMA/vimentin), and endothelial (CD31) features by spatial mass cytometry, with expected adenosine-pathway shifts – advocating clinical triplets (CD73 ± PD-L1 + chemo/RT) with mechanism-linked biomarkers (CD73 down-modulation, adenosine metabolites, TAM/CAF depletion on spatial mass cytometry) to confirm microenvironment reprogramming (48, 49).

Finally, CyTOF-anchored target discovery in human CRC suggests epigenetic nodes that regulate immune fitness. Han et al. linked high KAT6A to low CD8⁺ infiltration (CyTOF, IHC, and TCGA deconvolution concordant) and demonstrated that KAT6A inhibition restores interferon signaling (cGAS–STING–TBK1–IRF3 axis) and synergizes with anti-PD-1 in both MSS and MSI-H CRC models without overt toxicity. Clinically, KAT6A-low patients had higher ORR/DCR (e.g., ORR 49.1% vs. 10.4%) and longer progression-free survival (PFS)/overall survival (OS) on immunotherapy, nominating KAT6A as a biomarker and therapeutic target to enhance checkpoint efficacy – pending prospective validation to confirm predictive value independent of MSI or tumor mutational burden (TMB) (50).

An overview of the principal biomarkers identified through CyTOF and imaging mass cytometry studies, including their molecular characteristics, specimen type, biological function, and proposed clinical application as predictive, prognostic, or pharmacodynamic indicators is presented in Table II.

Roadmap for Clinical Translation of CyTOF in Colorectal Cancer

While CyTOF has unequivocally demonstrated its power as a research tool for exploring the complexities of cancer biology, its journey from the research bench to routine clinical practice presents significant logistical, technical, and financial challenges. To realize its clinical potential, it is essential to address issues of standardization, cost, data analysis, and integration with emerging technologies mentioned before. The successful transition from bench to bedside will require harmonization of protocols, validated bioinformatics pipelines, and a compelling demonstration of clinical utility.

Biological and clinical heterogeneity as a barrier to biomarker generalizability. Firstly, the scientific field must confront the challenge of biological and clinical heterogeneity in CRC. Tumor subtype, anatomical sidedness, microsatellite status, and prior therapies all shape immune and stromal dynamics in ways that complicate biomarker discovery (51, 52). Without large, diverse, and well-annotated patient cohorts, CyTOF studies risk producing context-specific signatures that lack generalizability. Establishing pooled biobanks and shared databases will be crucial to ensure that single-cell insights are reproducible across populations and translatable into clinical practice.

Barriers to clinical translation: standardization, validation, and cost-effectiveness. The foremost barrier to the clinical implementation of mass cytometry is the need for rigorous standardization and validation (53). For a diagnostic test to be reliable, its results must be reproducible across different laboratories, different technicians, and over long periods of time. This is particularly challenging for a complex technology like CyTOF, where variability can be introduced at every stage of the workflow. This includes pre-analytical variables in sample collection and processing (e.g., time from collection to fixation, cryopreservation protocols), analytical variables in the laboratory (e.g., antibody clones and concentrations, instrument calibration), and post-analytical variables in data processing.

To address these challenges, significant efforts are underway to develop standardized operating procedures (SOPs) and quality control measures. One promising approach is the development of lyophilized, pre-formulated antibody cocktails, such as the Maxpar Direct Immune Profiling Assay (54). These dry-format reagents offer long-term stability, reduce the potential for pipetting errors, and ensure that the same antibody panel is used consistently across sites in a multi-center clinical trial (54). Furthermore, methods for harmonization, such as the inclusion of standardized reference samples (e.g., peripheral blood mononuclear cells from a single healthy donor) in every experimental batch, can help to identify and computationally correct for batch effects, enabling the comparison of data generated at different times or in different locations (55). Achieving the level of standardization required for clinical certification [e.g., compliance with Good Clinical/Laboratory Practices (GCP/GLP) and ISO standards] is a complex but essential step for regulatory approval.

Economic barriers and the need for cost-effectiveness evidence. Beyond standardization, the financial barrier remains substantial. For CyTOF to become a routine clinical test, its cost-effectiveness must be clearly demonstrated. This would require demonstrating that the clinical insights provided by a CyTOF-based assay – for example, by accurately predicting response to an expensive therapy – lead to better patient outcomes and ultimately reduce overall healthcare costs by avoiding the use of ineffective treatments (56).

The bioinformatics bottleneck: From raw data to actionable insights. The conventional method of analyzing cytometry data, known as manual gating, involves a biologist sequentially drawing 2D plots to isolate cell populations based on the expression of two markers at a time (57). While effective for low-parameter flow cytometry, this approach is untenable for high-dimensional data. The number of possible 2D plots grows combinatorially with the number of markers, making an exhaustive manual analysis impossible. More importantly, manual gating is inherently subjective, labor-intensive, and poorly reproducible, making it unsuitable for a standardized clinical test (57).

To overcome this, a host of computational tools have been developed. These generally fall into two categories: dimensionality reduction algorithms for data visualization, and clustering algorithms for automated cell population identification. Dimensionality reduction tools like t-distributed Stochastic Neighbor Embedding (t-SNE) and Uniform Manifold Approximation and Projection (UMAP) are widely used to compress the high-dimensional data into a 2D map, where cells with similar protein expression profiles are placed close to each other, allowing for intuitive visualization of the cellular landscape (58-60). Unsupervised clustering algorithms, such as FlowSOM, PhenoGraph, or Citrus, then group these cells into distinct clusters based on their expression patterns, enabling the automated and unbiased identification of cell populations without a priori definitions (14).

While powerful for exploratory research, these tools present their own challenges for clinical translation. They often require significant computational expertise to run and interpret, and their outputs can be sensitive to parameter settings and technical artifacts like batch effects (61). The critical step for clinical implementation is to move beyond these exploratory tools to a “clinical-grade” bioinformatics pipeline. This requires the development of a locked-down, validated, and fully automated software system that can take the raw data from the instrument as input and produce a simple, quantitative, and clinically actionable report as output. This “sample-in, report-out” system would encapsulate the entire complex analysis – including quality control, batch correction, cell population identification, and the application of a validated predictive algorithm – into a seamless workflow that can be run reproducibly in a clinical laboratory setting. The development of such software, like the early-stage Maxpar Pathsetter, is as crucial for the future of clinical CyTOF as the development of the instrument hardware itself (54).

The future is spatial and integrated: Imaging mass cytometry and multi-omics. While suspension mass cytometry provides an unparalleled view of the composition of the TME, it does so at the cost of spatial information, as the tissue must be dissociated into a single-cell suspension. The next frontier in high-dimensional analysis is Imaging Mass Cytometry (IMC), a technology that combines the multiplexing power of CyTOF with immunohistochemistry to perform high-parameter analysis directly on intact tissue sections (62). In IMC, a tissue slide is stained with the same cocktail of metal-tagged antibodies. Then, a high-resolution laser is used to ablate the tissue spot-by-spot, and the ablated material from each spot is sent to the mass cytometer for analysis (62). By mapping the data from each spot back to its original coordinates, IMC reconstructs a highly multiplexed image of the tissue, revealing the expression of up to 50 proteins at subcellular resolution while preserving the complete spatial architecture of the TME (63). This revolutionary advance allows researchers to move beyond simply asking “what cells are present?” to asking “where are they located and who are they interacting with?” (64).

The potential of IMC to deepen our understanding of mCRC biology and therapeutic response is immense. It can be used to visualize critical immuno-oncology concepts that are invisible to suspension-based methods. For example, IMC can delineate immune exclusion zones, where T-cells are restricted to the tumor stroma and prevented from infiltrating the tumor nests. It can identify and characterize tertiary lymphoid structures (TLS), which are ectopic lymph node-like structures that can form within tumors and are associated with robust anti-tumor immunity and response to immunotherapy (65). Most importantly, it allows for the quantitative analysis of direct cell-to-cell interactions and the characterization of distinct cellular areas, providing a systems-level view of the spatial organization of the tumor ecosystem (66).

Looking further ahead, the ultimate goal is the integration of multiple single-cell, multi-omic datasets to create a complete, four-dimensional model of the tumor. This would involve combining the spatial proteomics of IMC with the deep suspension proteomics of CyTOF, the global transcriptome profiling of scRNA-seq, and single-cell genomic analyses. By integrating these layers of information from the same patient’s tumor, it will be possible to build a comprehensive understanding of how the genetic drivers of a cancer cell shape its proteomic signaling state, how that cell interacts with its neighbors in the TME, and how the entire ecosystem evolves over time and in response to therapy. This integrated, multi-modal approach represents the future of cancer research and will be the foundation upon which the next generation of truly personalized cancer therapies are built.

Concluding recommendations for research and clinical practice. Mass cytometry has emerged as a uniquely powerful technology for single-cell biology, offering an unprecedented depth of proteomic analysis that has already yielded significant and novel insights into the complex immune landscape of advanced CRC and the profound ways in which chemotherapy shapes it. It has moved our understanding beyond a tumor-centric, genetic-determinist view of the disease towards a more holistic, ecosystem-level perspective, where therapeutic outcome is understood as an emergent property of the dynamic interactions between cancer cells and the diverse components of the tumor microenvironment. However, the path from a powerful research tool to a routine clinical diagnostic is challenging and requires a clear, strategic vision. While CyTOF has immense potential to revolutionize response assessment and biomarker discovery in CRC, this potential will only be realized through concerted and systematic efforts in several key areas.

The primary recommendation for advancing the field is the systematic incorporation of mass cytometry (both suspension and imaging) as an integral exploratory endpoint in prospective clinical trials for CRC. This is particularly critical for trials investigating novel therapeutic combinations, such as new cytotoxic regimens or chemoimmunotherapy strategies (67). Only through the analysis of well-annotated clinical samples from patients with known treatment regimes and outcomes can we generate high-level evidence required to discover and validate CyTOF-derived cellular signatures as clinically meaningful predictive biomarkers. These studies must be designed with standardization, employing harmonized protocols for sample processing and analysis to ensure that data is robust, comparable, and reproducible across institutions.

Concurrently, the research community must continue to address the significant technical and bioinformatics challenges. Continued investment is needed in developing more affordable reagents, higher-throughput instrumentation, and, most critically, user-friendly, automated, and clinically validated analysis tools that can translate the immensely complex datasets into clear, actionable reports for clinicians.

Mass cytometry provides an unparalleled opportunity to explore the cellular mechanisms of chemotherapy response and resistance in advanced CRC. It allows us to ask and answer questions at a resolution that was previously unimaginable, moving us closer to the ultimate goal of precision oncology. While the challenges to its widespread clinical adoption are substantial, they are not insurmountable. Through collaborative research embedded within the framework of clinical trials, mass cytometry is poised to move beyond its current role in exploratory research, paving the way for a new era of biologically-informed, dynamic, and truly personalized therapy for colorectal cancer patients.